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What is already known about the topic?
•• Only a small number of studies have considered the cost to society of providing end of life care.
•• The costs of providing care to people with cancer at the end of their lives is significant.
•• No single study has considered the broad range of health, social and informal care that is provided to people at the end of 
life.
What this paper adds?
•• This study is the first to include the costs of health and social care as well as the cost of informal care giving when estimating 
the cost to society of providing care at the end of life.
•• Using a modelling-based approach, we estimate a total cost to society of caring for people with cancer as they approach the 
end of life.
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Abstract
Background: People with advanced cancer require a range of health, social and informal care during the final phases of life. The cost 
of providing care to this group as they approach the end of their lives is unknown, but represents a significant cost to health and social 
care systems, charities patients and their families.
Aim: In this study, we estimate the direct and indirect costs for lung, breast, colorectal and prostate cancer patients at the end of life 
(from the start of strong opioids to death) in England and Wales.
Methods: We use a modelling-based approach to estimate the costs of care. Data are estimated from the literature and publicly 
available data sets. Probabilistic sensitivity analysis is used to reflect uncertainty in model estimates.
Results: Total estimated costs for treating people with these four cancers at the end of life are £641 million. Breast and prostate 
cancer patients have the highest expected cost per person at £12,663 (95% credible interval (CI): £1249–£38,712) and £14,859 
(95% CI: £1391–£46,424), respectively. Lung cancer has the highest expected total cost (£226m). The value of informal care giving 
accounts for approximately one-third of all costs.
Conclusion: The cost to society of providing care to people at the end of their lives is significant. Much of this cost is borne by 
informal care givers. The cost to formal care services of replacing this care with paid care giving would be significant and demand for 
care will increase as the demographic profile of the population ages.
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•• We find that the costs of providing care are significant, with up to one-third of that cost being borne by informal care 
givers.
•• Sensitivity analysis reveals the limitations of the available data for estimating costs and planning services.
Implications for practice, theory or policy
•• Replacing informal care giving with formal services would represent a significant cost to public service providers.
•• Service planners should be aware of the role of informal care giving in meeting the care needs of people at the end of their 
lives.
•• Improved data collection and categorisation would allow for more informative international comparisons to drive service 
improvements.
Background
Cancer is responsible for over 141,000 deaths in England 
and Wales every year.1 It is a significant burden to individu-
als and society in terms of morbidity and mortality. The 
cost of providing care to people who die with and from can-
cer as they approach the end of their lives is unknown, yet 
clearly represents a significant cost to the health care sys-
tems, social services, charities and, importantly, patients 
and their families. In this study, we estimate the cost to 
society of providing care at the end of life to patients who 
die from lung, colorectal, breast or prostate cancer. The 
four cancers included here account for approximately 45% 
of all cancer-related deaths in England and Wales.1
Care for people with cancer in the advanced stages is 
provided by a wide range of specialist and generalist pro-
viders of health and social services.2 Health care will usu-
ally focus on maximising symptom control.3,4 It may 
encompass courses of palliative chemotherapy to reduce 
tumour size and spread, radiotherapy for localised bone 
pain or to manage acute emergencies such as superior vena 
caval obstruction or spinal cord compression. Drugs are 
commonly used to control the more widespread symptoms 
such as pain and nausea and vomiting. As illness pro-
gresses, fatigue and frailty lead to falls in global function-
ing and assistance with daily living may be needed. As 
death approaches, general nursing care support may be 
required provided by a mixture of generalist and specialist 
nursing services, either in the patient’s home or other care 
settings. Additional supportive care may be offered by a 
broad range of physicians with advice from specialist pal-
liative care providers or perhaps sharing care between pal-
liative and oncology specialists. Individuals or their 
families may be required to pay for residential or nursing 
home care, imposing significant financial burden and may 
also provide informal care at significant personal cost, par-
ticularly through foregone employment.5
The aim of this study is to estimate the total direct and 
indirect costs of the broad range of care described above 
provided to lung, colorectal, breast and prostate cancer 
patients in England and Wales during the end-of-life period 
– that is, the period in people’s lives where death is 
expected in the near future and the primary aims of treat-
ment are no longer curative.
Methods
Systematic review
To understand what is already known on this topic and to 
plan the methodology for our model-based approach, we 
began with a systematic review of the literature. We 
searched MEDLINE, Embase, PsycINFO, EconLit, 
CINAHL and NHSEED databases for studies published 
between 1990 and 1 April 2015. Grey literature was also 
searched for UK government or statutory agency reports, 
reports by non-governmental agencies or academic work-
ing papers. The review search strategy and further details 
are provided in the supplemental material.
We chose UK-based studies that included cancer 
patients for detailed review given the UK National Health 
Service (NHS) cancer care was the focus of our analysis. 
We included four UK-based studies that considered the 
cost of providing any type of care to patients with cancer at 
the end of life.6–9 All of the studies included in the review 
estimated the costs of providing health care, while three 
also included estimates of the costs of providing social 
care6,7,9 and none included the costs of privately provided 
care, charity provided care or informal care provision 
(Table 1). What little evidence is available suggests that 
there are significant direct and indirect costs in caring for 
patients at the end of their lives that are not met by public 
health and social care providers.5 These additional costs 
are a significant burden to individuals and society and 
need to be counted.
Defining the end-of-life period
Defining what constitutes end-of-life care is difficult, with 
different views taken at times by health service planners, 
researchers and the wider public.10–12 Within England and 
Wales, the definition used in practice is that contained in 
the Gold Standards Framework guidance document pro-
duced by the Royal College of General Practitioners10 and 
the National Institute for Health and Care Excellence 
(NICE) Quality Standards11 for end-of-life care. These 
state that a person is approaching the end of life when it is 
considered by health care professionals that they are likely 
to die within the next 12 months. This includes ‘People 
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whose death is imminent … as well as those with advanced, 
progressive, incurable conditions, general frailty and co-
existing conditions that mean they are expected to die 
within 12 months …’.12
This definition has limitations for research purposes. In 
our view, in order for a definition of the end of life period 
to be useful in a research context where service use or 
costs are to be estimated, it must satisfy two criteria, at 
least partially. First, there must be a defined period of time 
over which the research will be conducted. Second, it 
should reflect as far as possible the clinical needs of the 
patient. Using the 12 month time frame as above fails to 
satisfy this second criterion, as it may lead to an:
•• underestimate of costs for patients who may have 
palliative needs longer than 12 months, yet
•• overestimate of costs for those patients who are 
expected to die in under 12 months.
For this study, we consider that the most appropriate 
definition of the end of life should include patients who 
are at increased risk of death during the time period 
measured and should account for the varying lengths of 
time patients with different illnesses may spend with pal-
liative care needs. This approach also has the advantage 
that it is based on the clinical needs of the patient, rather 
than an indiscriminate fixed length of time, which reflects 
the recommendations of the Palliative Care Funding 
Review.13 We have chosen to follow the approach of 
Guest et al.8 in defining the end of life period as the point 
at which a patient begins the use of strong opioids. The 
use of strong opioids is the principal treatment for pain 
associated with advanced, progressive cancer.14 At this 
stage of disease, the primary intention of treatment is 
often the management of symptoms as cure is no longer 
likely.
The model
This analysis takes a novel approach to estimating a popu-
lation estimate of the cost of an illness. Using data availa-
ble in the literature, a model has been developed to estimate 
the cost of providing care to a typical patient during the 
end of life period. This estimate (along with associated 
estimates of uncertainty) is then aggregated to derive a 
population-level estimate. The model comprises counts of 
the resources used by an individual in the last period of life 
combined with an estimate of the unit cost for each of 
those resources. An estimated cost for an individual patient 
is calculated by summing the resources used during the 
end of life period multiplied by the unit cost of the resource. 
Monte Carlo simulations are conducted to generate an 
expected mean cost for an individual patient, reported with 
associated Bayesian credible intervals (posterior probabil-
ity interval).15 We conduct 10,000 simulations for each of 
the four cancers studied. This approach generates a plausi-
ble estimate of the overall cost based on the existing data; 
this is an improvement over existing cost of care methods, 
Table 1. Overview of studies included in review.
Study Population, study type Direct costs Indirect costs Results (mean cost)
Nuffield (2014)9 All deaths, with cancer sub-
group analysis. Retrospective 
cohort analysis.
Primary and community care, 
social care, inpatient hospice 
care, secondary care used in 
the 90 days prior to death.
None Per death – £6015
 Per cancer death – £7287
Nuffield (2012)6 Patients with long-term 
conditions (including 
cancer, chronic obstructive 
pulmonary disease, ischaemic 
heart disease, organ failure 
and mental disorders). 
Retrospective cohort analysis
Inpatient care, nursing care, 
residential care, home care, 
respite care, equipment, day 
care and direct payments in 
the 12 months prior to death.
None Per death – £10,130
 Per cancer death – 
£10,844
RAND (2008)7 Incidence-based population 
of patients who died from 
cancer or organ failure. 
Modelling study.
Hospital inpatient stays; 
hospice inpatient stays; home 
care costs per day in the 
12 months prior to death.
None Cancer, per patient: 
£14,236
 Organ failure, per patient: 
£18,771
Guest et al. (2006)8 Incidence-based population 
of patients with advanced 
cancer. Retrospective cohort 
analysis.
Prescriptions, GP use; 
palliative physician use (home 
and outpatient) and hospital 
admissions from the time 
of strong opioid use being 
instigated until death.
None Per patient:
 Breast – £1.75 k
 Colon – £1.54 k
 Lung – £2.24 k
 Uterus – £2.69 k
 Ovaries – 4.79 k
 Prostate – £3.77 k
 Stomach – 3.49 k
GP: general practitioner.
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as it gives a fuller account of the uncertainty inherent in the 
underlying data.
Because of the diffuse nature of the care provided, in 
diverse settings, and the need to include an estimate of 
informal care, we have chosen to estimate costs from the 
bottom-up.16 This approach requires detailed information 
on resource use and unit costs. Although this approach is 
more resource intensive than the alternative top-down 
approach (which aggregates data at the system level), it is 
the only practical way to arrive at a meaningful estimate of 
the costs of providing end of life care. Details of how we 
derived the estimates used in our analysis are provided in 
the supplementary material.
Unit costs
Unit costs have been estimated using publicly available 
data where possible. Both direct and indirect costs are con-
sidered in this study. Direct costs are those borne directly 
by the health or social care services, or patients and their 
carers. We include direct costs only for health and social 
care providers, as no data of sufficient quality were identi-
fied to include the direct costs to patients and their carers. 
Indirect costs are those costs arising from the illness but 
where a payment is not made, such as lost wages due to 
time off work. The key indirect cost included in this study 
relates to value of the provision of informal care. This has 
been valued using the human capital approach.17
Sensitivity analysis
The approach we took to estimating the cost of care relies 
on a number of parameter values that are uncertain. The 
role of sensitivity analyses is to demonstrate the degree to 
which results may be affected by this uncertainty in the 
data. Probabilistic sensitivity analysis combined with 
Monte Carlo simulation is used to address the uncertainty 
in the parameter estimates used in the model.
Results
Results are presented in Tables 5 and 6. As would be 
expected, the patients with the longest expected survival 
(breast and prostate cancers) are those who have the 
highest average expected cost per person during the last 
period of their lives (Table 5). Lung cancer leads to the 
most deaths and has the highest expected total cost of the 
four cancer types (Table 6). The total estimated cost of 
providing care to people with these four cancers is 
£642 million (Table 6). Health care and informal care 
provision represent the highest cost areas across all four 
cancer types. The financial value of charity care provi-
sion is low in our estimation, although this is probably 
an underestimate due to the way we have classified char-
ity care.
Discussion
Our results show that the costs of providing care to people 
with breast, prostate, colorectal or lung cancer at the end of 
their lives are significant. Our expected total direct and 
indirect costs for treating people at the end of life for these 
four cancers alone is nearly £650 million. This is clearly a 
significant cost to health and social care services directly, 
as well as indirectly to patients and their carers. About 
33% (£219 million) of the total costs of care are borne by 
informal carers in terms of the value of the care they pro-
vide and lost employment income. Direct health care costs 
during the end of life period for these four cancers alone 
are estimated at £275.3 million, compared to total health 
care costs for all cancer care provision in the United 
Kingdom of £5.24 billion.24
Our estimated costs differ from those studies included 
in our review (Table 1). In our study, the expected cost of 
care for each cancer across all four cancer types consid-
ered and resource categories is £9914, with expected costs 
of health and social care of £4254 and £1829, respectively. 
By comparison, the Nuffield study of 20126 estimated an 
average cost per cancer patient in the 12 months prior to 
death of £10,844, with health care accounting for £9498 
and social care £1346. The Nuffield estimate of overall 
cost per patient is higher than our overall estimate despite 
the fact that we included the value of a wider range of care 
(the Nuffield study did not include primary, informal or 
hospice care provision). The difference in costs appears to 
be driven largely by the estimated health care costs in each 
analysis. This in turn appears to be largely due to the way 
the end of life period is defined. Results from our simula-
tion show that patients across all four cancer types have an 
expected survival of 243 days from when they enter the 
end of life period as defined for our study, compared with 
the 365-day period considered as end of life in the Nuffield 
study. The fact that this survival time accounts for much of 
the difference between estimates highlights how important 
defining the end of life period is for undertaking analysis is 
in this area, whether for estimates of cost or for other ser-
vice planning purposes.
The value of care provided by charities was lower than 
we anticipated. This is most likely an underestimate, as 
charities provide care through multiple avenues and iden-
tifying spending in each case is difficult. Our results sug-
gest that charities provide just £30 million pounds of care 
per year through hospice provision – this reflects the fact 
that just 5% of the population will die in a hospice and will 
spend a relatively short period of time there. But charities 
also provide care through other means, often paid for in 
part by local authorities and the health service – these costs 
will have been captured where possible in the social care 
element of spending, and though charity provided and sub-
sidised, it will not be included in the estimate of charitable 
provision.
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Table 2. Estimates of resource use.
Category Mean Distribution α β Source
Expected survival (days)
 Breast cancer 372 Gamma 1.00 372 Guest et al.8
 Colorectal cancer 201 Gamma 1.00 201 Guest et al.8
 Lung cancer 180 Gamma 1.00 180 Guest et al.8
 Prostate cancer 360 Gamma 1.00 360 Guest et al.8
Health care resource use
 Estimates used for all cancers
  Probability any hospital care 0.99 Beta 19,828 106 Georghiou et al.6
  Mean annual elective inpatient admissionsa 2.51 Gamma 1.00 2.51 Georghiou et al.6
   Mean annual non-elective inpatient 
admissionsa
1.95 Gamma 1.00 1.95 Georghiou et al.6
  Outpatient attendances 10.80 Gamma 1.00 10.80 Georghiou et al.6
  A&E attendances 1.39 Gamma 1.00 1.39 Georghiou et al.6
Breast cancer
 Probability non-emergency admissiona 0.97 Beta 172,504 5010 Hospital Episode 
Statistics (C50)18
 Probability emergency admissiona 0.03 Beta 4810 172,704 Hospital Episode 
Statistics (C50)18
 Mean days per inpatient admission 3.00 Gamma 1.00 3.00 Hospital Episode 
Statistics (C50)18
 GP contacts (at surgery) 15.75 Gamma 1.00 15.75 Guest et al.8
 District Nurse contacts 15.75 Gamma 1.00 15.75 Guest et al.8
Colorectal cancer
 Probability non-emergency admissiona 0.92 Beta 128,811 11,464 Hospital Episode 
Statistics (C18-C20)18
 Probability emergency admissiona 0.08 Beta 11,464 128,811 Hospital Episode 
Statistics (C18-C20)18
 Mean days per inpatient admission 9.80 Gamma 1.00 9.80 Hospital Episode 
Statistics (C18-C20)18
 GP contacts (at surgery) 10.43 Gamma 1.00 10.43 Guest et al., 20068
 District Nurse contacts 10.43 Gamma 1.00 10.43 Guest et al., 20068
Prostate cancer (C61)
 Probability non-emergency admissiona 0.91 Beta 51,566 5090 Hospital Episode 
Statistics (C61)18
 Probability emergency admissiona 0.09 Beta 5090 51,566 Hospital Episode 
Statistics (C61)18
 Mean days per inpatient admission 5.60 Gamma 1.00 5.60 Hospital Episode 
Statistics (C61)18
 GP contacts (at surgery) 14.97 Gamma 1.00 14.97 Guest et al.8
 District Nurse contacts 14.97 Gamma 1.00 14.97 Guest et al.8
Lung cancer (C34)
 Probability non-emergency admissiona 0.81 Beta 68,340 16,536 Hospital Episode 
Statistics (C34)18
 Probability emergency admissiona 0.19 Beta 16,536 68,340 Hospital Episode 
Statistics (C34)18
 Mean days per inpatient admission 8.80 Gamma 1.00 8.80 Hospital Episode 
Statistics (C34)18
 GP contacts (at surgery) 21.76 Gamma 1.00 21.76 Guest et al.8
 District Nurse contacts 21.76 Gamma 1.00 21.76 Guest et al.8
Social care resource use
 Probability of any home care use 0.13 Beta 0.75 3574.00 Georghiou et al.6
 Mean days of home care usea 57.25 Gamma 1.00 57.25 Georghiou et al.6
 Hours per day of home care use 1.20 Gamma 1.00 1.20 Georghiou et al.6
 Probability of being in a nursing home 0.03 Beta 519.00 19,415.00 Georghiou et al.6
(Continued)
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Our study is the only one to date to acknowledge and 
capture, using probabilistic sensitivity analysis, the full 
extent of the uncertainty surrounding the level of resources 
used by patients at the end of life. The wide 95% credible 
intervals indicate that our results are highly uncertain and 
thus how uncertain knowledge of the cost of providing end 
of life care is. This uncertainty is driven by two things. The 
first is that many of the estimates we were able to identify 
for resource use are themselves highly uncertain. In many 
cases, only a point estimate was reported in the existing 
research – for example, while Guest et al.8 report in some 
detail the different categories of resources used, they did 
not report confidence intervals or any other measure of 
dispersion. As a result, it was necessary in some cases to 
make highly conservative assumptions about the variabil-
ity of patient resource use in the model. It is a necessary 
consequence of making such conservative assumptions 
that we increase the uncertainty in our results. The second 
is that in many cases, it was not possible to find data that 
applied specifically to patients at the end of life. This again 
leads to conservative assumptions and greater uncertainty 
in results. Better collection of routine data would enable 
analysts and service planners to understand better patterns 
of resource use, including at the end of life.
Additionally, there is a lack of distinction in recorded 
statistics between care that happens because a patient is at 
the end of life that is primarily palliative in intent, and all 
other care a patient receives during this time. This makes 
estimation of a cost of care for people at the end of life 
difficult. This is a problem faced by many researchers 
interested in establishing what care individuals receive 
towards the end of life. We have taken the pragmatic 
approach, which is to consider all care at the end of life. 
But in some cases, patients with co-morbidities would be 
receiving care irrespective of their cancer diagnosis. 
However, as data are not coded to indicate whether or not 
care is because of the end of life being reached, it is not 
possible to take any other approach. This lack of data may 
also present problems to those in charge of commissioning 
or designing services.
A lack of widely available data also restricts compari-
sons between countries. In the systematic review, we 
identified an additional six studies which estimated the 
cost of providing care to patients at the end of life in non-
UK countries.6–11 In addition to not being UK-based, 
none of these studies focused exclusively on cancer 
patients and so were excluded from the review. Direct 
comparisons of costs between different health economies 
are difficult – palliative and end of life care can constitute 
a wide range of different services and patient needs can 
be met in a wide range of ways. Yet, without reliable data 
on who gets what care, when and where, and at what cost, 
it is difficult to make a comparative assessment of out-
comes internationally. For example, a recent study from 
Canada found that the cost of caring for an individual 
was approximately CAD34,000 (£185,000).25 However, 
given differences in the structure of the care system and 
definitions of the end of life period, it is not possible to 
Category Mean Distribution α β Source
 Days in nursing homea 55.28 Gamma 1.00 55.28 Georghiou et al.6
 Probability of being in a residential home 0.04 Beta 794.00 19,140.00 Georghiou et al.6
 Days in residential homea 66.77 Gamma 1.00 66.77 Georghiou et al.6
 Probability of ‘Other Social Care’ use 0.02 Beta 0.96 43.34 Georghiou et al.6
 Units of ‘Other Social Care’ useda 5.00 Gamma 1.00 5.00 Georghiou et al.6
Charity provided care
 Probability hospice inpatient stay 0.05 Beta 0.91 18.37 Marie Curie Cancer 
Care data
 Hospice inpatient daysa 22.91 Gamma 1.00 22.91 Marie Curie Cancer 
Care data
 Probability hospice outpatient contact 0.05 Beta 0.91 18.37 Marie Curie Cancer 
Care data
 Hospice outpatient visitsa 5.85 Gamma 1.00 5.85 Marie Curie Cancer 
Care data
Informal care
 Probability of receiving any informal care 0.34 Beta 0.32 0.62 Hayman et al.19
 Hours of informal care received (weekly)a 15.00 Gamma 1.00 15.00 Macmillan Cancer 
Support5
 Hours of employment lost by carer (weekly)a 2.18 Gamma 10.06 0.22 Macmillan Cancer 
Support5
 Probability carer’s allowance received by carera 15.00 Beta 0.90 17.10 Macmillan Cancer 
Support5
GP: general practitioner.
aThese parameters are set equal to 0 where the individual did not use a resource.
Table 2. (Continued)
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make a direct comparison between studies. This restricts 
further development of cost-effective services and pre-
vents others from drawing on knowledge and experience 
gained elsewhere. A more useful comparison would be to 
explore resource use differences between countries; how-
ever, there are insufficient data from the identified stud-
ies to conduct such an analysis. We expect that the costs 
of caring for people at the end of life are likely to be 
significant in all countries, yet differences in the structure 
Table 3. Unit costs (all costs adjusted to 2013–2014 prices).
Category Unit cost Source
Health care resources
Breast cancer
 Elective inpatient admission (initial spell) £362 2013–14 Tariff, JA12C Malignant breast disorder without CC20
 Elective inpatient admission (excess day) £227 2013–14 Tariff, JA12C Malignant breast disorder without CC20
 Non-elective inpatient admission £964 2013–14 Tariff, JA12C Malignant breast disorder without CC20
 Non-elective inpatient admission (excess day) £227 2013–14 Tariff, JA12C Malignant breast disorder without CC20
Colorectal cancer
 Elective inpatient admission (initial spell) £1756 2013–14 Tariff, FZ46B Malignant Large Intestinal Disorders 
with length of stay 2 days or more without Major CC20
 Elective inpatient admission (excess day) £218 2013–14 Tariff, FZ46B Malignant Large Intestinal Disorders 
with length of stay 2 days or more without Major CC20
 Non-elective inpatient admission £2829 2013–14 Tariff, FZ46B Malignant Large Intestinal Disorders 
with length of stay 2 days or more without Major CC20
 Non-elective inpatient admission (excess day) £218 2013–14 Tariff, FZ46B Malignant Large Intestinal Disorders 
with length of stay 2 days or more without Major CC20
Lung cancer
 Elective inpatient admission (initial spell) £761 2013–14 Tariff, DZ17C Respiratory Neoplasms without CC20
 Elective inpatient admission (excess day) £195 2013–14 Tariff, DZ17C Respiratory Neoplasms without CC20
 Non-elective inpatient admission £2071 2013–14 Tariff, DZ17C Respiratory Neoplasms without CC20
 Non-elective inpatient admission (excess day) £195 2013–14 Tariff, DZ17C Respiratory Neoplasms without CC20
Prostate cancer
 Elective inpatient admission (initial spell) £1421 2013–14 Tariff, LB06F Kidney, Urinary Tract and Prostate 
Neoplasms with length of stay 2 days or more without CC20
 Elective inpatient admission (excess day) £205 2013–14 Tariff, LB06F Kidney, Urinary Tract and Prostate 
Neoplasms with length of stay 2 days or more without CC20
 Non-elective inpatient admission £1915 2013–14 Tariff, LB06F Kidney, Urinary Tract and Prostate 
Neoplasms with length of stay 2 days or more without CC20
 Non-elective inpatient admission (excess day) £205 2013–14 Tariff, LB06F Kidney, Urinary Tract and Prostate 
Neoplasms with length of stay 2 days or more without CC20
Common health care unit costs
 Outpatient appointment (Initial) £223 2013–14 Tariff, Clinical Oncology, Multi-Prof20
 Outpatient appointment (follow-up) £105 2013–14 Tariff, Clinical Oncology, Multi-Prof20
 A&E visit £102 VB05Z Category 2 investigation with category 3 treatment20
 District nurse £64 PSSRU 201121
 GP £36 PSSRU 201121
Social care resources
 Home care per hour £17 PSSRU via Nuffield6
 Nursing home per day £646 PSSRU via Nuffield6
 Residential home per day £529 PSSRU via Nuffield6
  Unit of ‘Other Social Care’ (day care, direct 
payments and respite care)
£2698 Nuffield6
Charity provided resources
 Hospice inpatient per day £419 Marie Curie Cancer Care data provided to the authors
 Hospice outpatient visit £104 Marie Curie Cancer Care data provided to the authors
Informal care
 Hour of lost employment £13 ONS 2011 Annual Survey of Hours and Earnings22
 Carer’s allowance per week £61 https://www.gov.uk/carers-allowance/overview
GP: general practitioner; CC: cancer care; PSSRU: Personal Social Services Research Unit; ONS: Office of National Statistics.
Table 4. Annual deaths by cancer type.
Cancer type Annual deaths
Breast 10,311
Colorectal 14,441
Lung 30,273
Prostate 9698
Source: Office of National Statistics.23
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of health and social care systems require analysis to be 
conducted on a country by country basis. The methods 
we describe in this analysis could be adapted to a range 
of settings in future research focusing on other health 
systems.
One of our most important findings is the value of the 
care provided to people at the end of life by informal car-
ers. The cost to the health and social care services to 
replace informal unpaid care giving with formal paid care 
giving would be significant. This has important policy 
implications. If current demographic trends continue, the 
proportion of older people requiring care will continue to 
increase, with fewer people capable of providing it. This 
also has implications for hospice services, which are 
highly dependent on volunteers at present.26 If the pool of 
capable informal carers and volunteers shrinks relative to 
the population needing care, a greater need for state fund-
ing will arise. Commissioners and payers of formal care 
services should be aware of this, as it may lead to greater 
pressure on resources than are currently expected.
Conclusion
As we have shown, the cost to society of providing care to 
people with one of the four studied cancers at the end of 
life is significant. For the individual patient, the mean 
expected cost of care to society is nearly £13,000. Across 
the roughly 140,000 people who die from cancer each 
year, this is a considerable sum. If we then consider that 
between 69% and 82% of the nearly 500,000 deaths in 
England and Wales will have palliative care needs, it is 
clear that providing this care is a great cost to society 
directly and indirectly. Much of this cost is borne by infor-
mal care givers. As populations age, there will be a greater 
demand for care and a decrease in the supply of informal 
care givers. Service planners should account for these 
issues when considering the future cost of providing end 
of life care.
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Table 5. Mean estimated cost per patient, by cancer type and resource use category, with Bayesian credible intervals.
Cancer type Health care Social care Charity care Informal care Total
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
Breast £4346 £2843 £480 £4868 £12,663
(£395 to £12,545) (£84 to £10,170) (£7 to £1845) (£18 to £21,818) (£1249 to £38,712)
Colorectal £4854 £1489 £470 £2850 £9760
(£413 to £14,485) (£44 to £5350) (£6 to £1833) (£10 to £13,350) (£1037 to £29,545)
Lung £3157 £1358 £459 £2420 £7467
(£332 to £8944) (£39 to £4838) (£6 to £1775) (£9 to £11,153) (£855 to £21,663)
Prostate £6687 £2728 £482 £4814 £14,859
(£535 to £20,257) (£83 to £9588) (£6 to £1906) (£18 to £21,981) (£1391 to £46,424)
Meana £4254 £1829 £468 £3265 £9914
CI: credible interval.
Based on 10,000 Monte Carlo simulations.
aMean weighted by proportion of deaths due to each cancer in the total population (Table 4).
Table 6. Mean estimated total cost of care, by cancer type and resource category (millions), with Bayesian credible intervals.
Cancer type Health care Social care Charity care Informal care Total
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
Breast £44.82  
(£4.07–£129.35)
£29.31  
(£0.86–£104.86)
£4.95  
(£0.07–£19.02)
£50.20  
(£0.19–£224.97)
£130.57  
(£12.88–£399.16)
Colorectal £70.10  
(£5.96–£209.18)
£21.51  
(£0.64–£77.25)
£6.79  
(£0.09–£26.47)
£41.16  
(£0.15–£192.79)
£140.95  
(£14.98–£426.66)
Lung £95.57  
(£10.05–£270.78)
£41.11  
(£1.18–£146.47)
£13.90  
(£0.17to £53.72)
£73.25  
(£0.27–£337.65)
£226.06  
(£25.90–£655.81)
Prostate £64.85  
(£5.19–£196.45)
£26.46  
(£0.81–£92.98)
£4.68  
(£0.06–£18.49)
£46.69  
(£0.17–£213.17)
£144.11  
(£13.49–£450.22)
Sub-totals £275.33 £118.39 £30.32 £211.29 £641.68
CI: credible interval.
Based on 10,000 Monte Carlo simulations.
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